论文部分内容阅读
[目的]比较观察厄洛替尼(erlotinib)与化疗治疗老年非小细胞肺癌(NSCLC)的治疗效果及不良反应。[方法]76例经病理学或细胞学确诊的老年NSCLC患者(≥65岁),分为两组,试验组42例,服用厄洛替尼(150mg,口服,每天1次)治疗直至病情进展或出现严重不良反应;对照组34例,给予以铂为基础的两药联合方案或单药化疗。[结果]厄洛替尼组和化疗组的客观有效率分别为31.0%(13/42)和25.0%(8/32),疾病控制率分别为69.0%(29/42)和65.6%(21/32),疾病进展时间分别为6.5个月和5.9个月,中位生存时间分别为8个月和7.2个月,厄洛替尼组的不良反应主要为皮疹和腹泻,多为Ⅰ度～Ⅱ度,无因不良反应需停药者,化疗组不良反应主要为白细胞下降、呕吐和脱发,多为Ⅰ度～Ⅱ度,有2例患者在第一周期化疗后出现Ⅳ度白细胞下降而停止化疗,改用厄洛替尼治疗。[结论]厄洛替尼治疗老年晚期NSCLC疗效不差于化疗,但不良反应比化疗小,有较好的疗效及安全性。
[Objective] To compare the therapeutic effects and adverse reactions of erlotinib with chemotherapy in the treatment of elderly non-small cell lung cancer (NSCLC). [Methods] A total of 76 elderly NSCLC patients (≥65 years old) diagnosed by pathology or cytology were divided into two groups. The treatment group received 42 erlotinib (150 mg orally once daily) until the disease progressed Or serious adverse reactions; control group of 34 patients, given platinum-based combination of two drugs or single-agent chemotherapy. [Results] The objective effective rates in the erlotinib group and the chemotherapy group were 31.0% (13/42) and 25.0% (8/32) respectively, and the disease control rates were 69.0% (29/42) and 65.6% (21/21) respectively / 32), the disease progression time was 6.5 months and 5.9 months, the median survival time was 8 months and 7.2 months, the adverse reactions of erlotinib group mainly rash and diarrhea, mostly Ⅰ degree ~ Ⅱ degree, no adverse reactions due to withdrawal, chemotherapy group were mainly leukopenia, vomiting and alopecia, mostly Ⅰ degree ~ Ⅱ degree, 2 patients in the first cycle of chemotherapy after Ⅳ leukopenia and stop Chemotherapy, switch to erlotinib treatment. [Conclusion] The efficacy of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC) is not worse than that of chemotherapy. However, the side effects of erlotinib are less than that of chemotherapy, and have good efficacy and safety.